Log In
BCIQ
Print this Print this
 

DIASTAT anti-CCP assay

  Manage Alerts
Collapse Summary General Information
Company Alere Inc.
DescriptionDetect autoantibodies against second generation cyclic citrullinated peptides in human serum or plasma (CCP2)
Molecular Target
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentMarketed
Standard IndicationAutoimmune, Diagnostic
Indication DetailsDiagnosis of RA in early synovitis patients
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$8,400.0M

$5,800.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/01/2016

$8,400.0M

$5,800.0M

0

Get a free BioCentury trial today